interstitial lung disease

(redirected from Lung fibrosis)

interstitial lung disease (ILD)

a respiratory disorder characterized by a dry, unproductive cough and dyspnea on exertion. The patient may have swallowing disorders or joint and muscle pain and a history of industrial exposure to inorganic dusts, such as asbestos or silica. X-ray films usually show fibrotic infiltrates in the lung tissue, usually in the lower lobes. The fibrosing or scarring of lung tissue is often the result of an immune reaction to an inhaled substance. However, interstitial lung disease may result from viral, bacterial, or other infections; uremic pneumonitis; cancer; a congenital or inherited disorder; or circulatory impairment. The condition may be self-limiting, progress to respiratory or cardiac failure, or undergo spontaneous recovery.

interstitial lung disease

Diffuse interstitial pulmonary fibrosis Pulmonology A group of disorders characterized by scarring of deep lung tissue, leading to SOB and loss of functional alveoli, limiting O2 exchange; ILD is more common in smokers Etiology Inorganic and organic dusts, gases, fumes, vapors, medications, radiation, and certain lung infections, hypersensitivity pneumonitis, coal worker's pneumoconiosis, silicosis, byssinosis, idiopathic

Interstitial lung disease

About 180 diseases fall into this category of breathing disorders. Injury or foreign substances in the lungs (such as asbestos fibers) as well as infections, cancers, or inherited disorders may cause the diseases. They can lead to breathing or heart failure.
Mentioned in: Chest X Ray
References in periodicals archive ?
06 (ANI): Restoring lipid synthesis could reduce lung fibrosis, a new study has revealed.
The primary endpoint of this randomized, double-blind, placebo-controlled, descriptive trial was change in relative QLF score, which uses high resolution CT imaging to measure the extent of lung fibrosis (thickening and scarring of the lungs), from baseline to 6 months of treatment.
NXP002 provides a route into the large, emerging fibrosis market, currently estimated at over USD 1bn in the US for lung fibrosis alone, with a safe and innovative treatment.
This is the first time anyone has generated potentially therapeutic lung stem cells from minimally invasive biopsy specimens, the authors said, adding that the properties of these cells make them potentially therapeutic for a wide range of lung fibrosis diseases.
In the lung, repeated injury to the delicate alveolar parenchyma may lead to progressive interstitial fibrosis, and lung fibrosis is a cardinal feature of a variety of diseases.
These days, we are witnessing more cases of lung fibrosis, chronic obstructive pulmonary disease and chronic asthma getting more severe.
We have also seen great demand for models of lung fibrosis and pulmonary artery hypertension, which reflects the unmet needs in these disease areas and the research efforts being expended by pharmaceutical companies.
CAT-scan revealed interstitial lung fibrosis change on both lungs and obvious ground-glass opacities on the right upper lung [Figure 1]a.
Rates of Lung fibrosis are climbing up menacingly since past five years.
The agreement also grants Bristol-Myers Squibb the option to receive exclusive licenses for HSP47 siRNAs in vitamin A containing formulations for the treatment of lung fibrosis and other organ fibrosis.
To confirm the role of estrogen in determining SPP1 levels and silica-induced lung fibrosis, we pretreated male mice with estrogen for 21 days prior to silica administration.